Breaking News

Biogen Appoints Value-Based Medicine VP

May 12, 2014

Rudick bring expertise in MS programs

Richard (Rick) A. Rudick, M.D., has been appointed vice president of Development Sciences, Value-Based Medicine, at Biogen Idec. He reports to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.
 
Dr. Rudick will lead the newly created Value-Based Medicine Group that focuses on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis (MS). The group emphasizes more evidence-based, individualized treatment options with the goal of improving care.   
 
Dr. Rudick has played key roles in several MS clinical trials, including the trials of Biogen’s products AVONEX (interferon beta-1a) and TYSABRI (natalizumab). Dr. Rudick joins the company from the Cleveland Clinic, where he served as director of the Mellen Center for Multiple Sclerosis Treatment and Research for nearly 30 years.
 
“Rick has been a valued partner of the company for more than two decades. Through his years of hands-on clinical experience, he has gained a truly unique understanding of the needs of MS patients,” said Dr. Sandrock. “His vision, expertise and passion bolsters our efforts to create real-world, practical solutions to empower better decision-making and improve the way people live with MS.”
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research